MetaCap

AIM ImmunoTech (AIM) vs Curis (CRIS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AIM ImmunoTech is the larger company by market cap ($4.6 million vs $4.1 million), about 1.1 times the size, while Curis is growing revenue faster (-13.4% vs -48.2%). Curis converts more of its revenue into profit, with a net margin of -80.3% versus -15861.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AIM-37.31%CRIS-42.03%
+56%+1%-54%
Oct 7, 20261 yearNov 20, 2026
AIM-36.33%CRIS-36.38%
+39%-4%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AIM versus CRIS key metrics
MetricAIMCRIS
Share price$0.1146$0.427
Market cap$4.57M$4.06M
1-day change-4.50%-9.03%
P/E ratio (TTM)—0.03
EPS (TTM)$-1.20$15.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$88.00K$9.44M
Revenue growth (YoY)-48.24%-13.43%
Net income (latest FY)$-13.96M$-7.58M
Operating margin-13254.55%-60.50%
Net margin-15861.36%-80.29%
52-week high$1.82$28.40
52-week low$0.1068$0.33
Distance from 52-week high-93.72%-98.50%
Analyst consensusnonenone
Avg. price target upside+3608.55%+9892.97%
Average volume4.40M4.33M
Shares outstanding39.92M9.51M
Employees1920
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Curis is more profitable, keeping -80.3 cents of every revenue dollar as net income versus -15861.4 cents for AIM ImmunoTech.
  • Curis grew revenue faster in its latest fiscal year (-13.43% vs -48.24%).

About AIM ImmunoTech

AIM stock →

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

About Curis

CRIS stock →

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

AIM vs CRIS FAQ

Which is bigger, AIM ImmunoTech or Curis?

AIM ImmunoTech (AIM) is larger, with a market capitalization of $4.57M compared with $4.06M for Curis (CRIS).

Are AIM ImmunoTech and Curis in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons